Last Update: Aug 19, 2026 A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever ClinicalTrials.gov Identifier: [NCT06006559](https://clinicaltrials.gov/ct2/show/NCT06006559) Novartis Reference Number:CEYU688A12201 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever. This is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of EYU688 administered orally in patients with dengue fever. Due to the different PK sampling schedules applied, the study consists of two cohorts run in parallel (intensive PK \\\[cohort 1\\\] and sparse PK sampling \\\[cohort 2\\\]). Condition Dengue Phase Phase2 Overall Status Recruiting Number of Participants108 Start Date Feb 20, 2024 Completion Date Jul 30, 2027 Gender All Age(s) 18 Years - 60 Years (Adult) ## Interventions Drug ### EYU688 EYU688 administered by oral route Drug ### Placebo Matching placebo administered orally as capsules ## Eligibility Criteria Inclusion Criteria: \* Male or female, 18 - 60 years old (inclusive). \* History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection: \* Nausea or vomiting. \* Presence of rash, aches or pains including headache, muscle or joint pain. \* Onset of fever ≤ 48 hours prior to treatment start. \* Positive test on dengue fever. Exclusion Criteria: \* Participants with any of abnormalities of clinical laboratory parameters. \* Usage of any anticoagulant drugs. \* Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug. \* Pregnant or nursing (lactating) women. \* Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening. \* Participants with any of the following abnormalities of clinical laboratory parameters at screening: \* Hemoglobin \\<12.0 g/dL in males; \\<11.0 g/dL in females \* Hematocrit \\>52 % in males; \\>46 % in females \* Absolute neutrophil count \\<1500/μL \* Platelet count \\<80,000/mm3 \* Creatinine \\>165 μmol/L in males; \\>130 μmol/L in females \* Serum creatine kinase \\> 600 U/L \* ALT, AST levels more than 3 X upper limit of normal (ULN) \* Total bilirubin \\>24 μmol/L \* Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening. \* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug. \* History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening: \* QTcF \\> 450 msec (males) \* QTcF \\> 460 msec (females) Other protocol-defined inclusion/exclusion criteria may apply. Brazil #### Novartis Investigative Site Recruiting São José do Rio Preto,São Paulo,15090 000,Brazil #### Novartis Investigative Site Recruiting São Caetano do Sul,São Paulo,09521-160,Brazil #### Novartis Investigative Site Recruiting Porto Alegre,Rio Grande do Sul,90560-032,Brazil #### Novartis Investigative Site Recruiting Manaus,Amazonas,69040-000,Brazil #### Novartis Investigative Site Recruiting Rio de Janeiro,Rio de Janeiro,21040-360,Brazil #### Novartis Investigative Site Recruiting Sorocaba,São Paulo,18040-425,Brazil #### Novartis Investigative Site Recruiting Brasília,Federal District,71635-580,Brazil Colombia #### Novartis Investigative Site Recruiting Bucaramanga,Santander Department,681017,Colombia #### Novartis Investigative Site Recruiting Barranquilla,Atlántico,080012,Colombia #### Novartis Investigative Site Recruiting Cali,Valle del Cauca Department,760032,Colombia India #### Novartis Investigative Site Recruiting Jaipur,Rajasthan,302017,India #### Novartis Investigative Site Recruiting Pune,Maharashtra,411013,India #### Novartis Investigative Site Recruiting Chennai,Tamil Nadu,600113,India #### Novartis Investigative Site Recruiting Belagavi,Karnataka,590010,India Malaysia #### Novartis Investigative Site Recruiting Kuantan,Pahang,25200,Malaysia #### Novartis Investigative Site Recruiting Kuala Selangor,68000,Malaysia #### Novartis Investigative Site Recruiting Ipoh,Perak,30450,Malaysia #### Novartis Investigative Site Recruiting Miri,Sarawak,98000,Malaysia #### Novartis Investigative Site Recruiting Seberang Jaya,Pulau Pinang,13700,Malaysia Mexico #### Novartis Investigative Site Recruiting Oaxaca City,68020,Mexico #### Novartis Investigative Site Recruiting Veracruz,91855,Mexico Singapore #### Novartis Investigative Site Recruiting Singapore,169608,Singapore #### Novartis Investigative Site Recruiting Singapore,Singapore,308433,Singapore Vietnam #### Novartis Investigative Site Recruiting Haiphong,180000,Vietnam #### Novartis Investigative Site Recruiting Ho Chi Minh City,700000,Vietnam #### Novartis Investigative Site Recruiting Hanoi,100000,Vietnam ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: